Chronic Pain – Landscape & Forecast – Disease Landscape & Forecast
A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug classes, including nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics. However, opioid analgesics, a cornerstone of chronic pain treatment, are under intense scrutiny from the public, payers, and prescribers; such scrutiny provides further opportunities for developers of agents with less risk of abuse or deterrence, agents that are safer and more tolerable, and drugs with novel mechanisms of action (MOAs), such as biologics targeting nerve growth factor (NGF). The emergence of agents with novel MOAs and the increase in prevalence of key subpopulations (e.g., osteoarthritic (OA) pain, chronic low back pain) will, in part, drive market growth.
QUESTIONS ANSWERED:
- How do interviewed experts perceive the chronic pain therapy market to be changing given the emphasis on the risk of abuse / misuse with opioid analgesics?
- How influential are abuse-deterrent formulations of extended-release / long-acting opioid analgesics on U.S. physicians’ prescribing for severe chronic pain?
- What will be the impact of new analgesics from various drug classes, most notably the first-in-class anti-NGF biologic therapies, given their reputed robust efficacy counterbalanced with safety risks, on the highly genericized chronic pain therapy market?
- What are the greatest areas of unmet need in the treatment of chronic pain, and how are the emerging therapies expected to address these unmet needs?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 41 country-specific interviews with thought-leading primary care physicians, pain specialists, neurologists, rheumatologists, and anesthesiologists. Supported by survey data collected for other DRG research.
Epidemiology: Prevalence, diagnosed, and drug-treated rates of chronic pain subpopulations by country, specifically cancer pain, chronic low back pain, fibromyalgia, and painful diabetic neuropathy; diagnosed prevalence of rheumatoid arthritis pain, OA pain, and postherpetic neuralgia, by country.
Forecast: Five- and ten-year drug-level sales of key chronic pain therapies through 2028; forecast base-year segmentation by select chronic pain populations.
Emerging Therapies: Phase II: 21 drugs; Phase III / preregistration / registration: 12 drugs.
Table of contents
- Chronic Pain - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Q4 2021
- December 2021
- Q3 2021
- July 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q1 2021
- Q4 2021
- Key Findings
- Chronic Pain - Key Findings - December 2021
- Chronic Pain - Key Findings - December 2021
- Market Outlook
- Key Findings
- Market Share of Chronic Pain by Indication: 2020
- Market Share of Drug Classes for Chronic Pain: 2020
- Market Share of Drug Classes for Chronic Pain: 2030
- Chronic Pain SWOT Analysis
- Market Drivers and Constraints
- What Factors Are Driving the Market for Chronic Pain?
- What Factors Are Constraining the Market for Chronic Pain?
- Regional Chronic Pain Drug Market: 2020-2030
- COVID-19: Forecast Impact
- Drug-Class-Specific Trends
- Antidepressants
- Market Share of Antidepressants for Chronic Pain: 2020-2030
- Antiepileptic Drugs
- Market Share of Antiepileptic Drugs in Chronic Pain: 2020-2030
- NSAIDs
- Market Share of NSAIDs for Chronic Pain: 2020-2030
- COX-2-Selective NSAIDs
- Market Share of COX-2-Selective NSAIDs for Chronic Pain: 2020-2030
- Opioid Analgesics
- Market Share of Opioid Analgesics in Chronic Pain: 2020-2030
- Dual-Acting Opioid Analgesics
- Market Share of Dual-Acting Opioid Analgesics in Chronic Pain: 2020-2030
- Opioid Combinations (NSAIDs / Acetaminophen)
- Local Anesthetics
- TRPV1 Agonists
- Market Share of TRPV1 Agonists in Chronic Pain: 2020-2030
- Subtype-Selective Sodium Channel Antagonists
- Anti-NGF Therapies
- Regional Sales of Anti-NGF Therapies in Chronic Pain: 2020-2030
- Cytokine Inhibitors
- Market Share of Cytokine Inhibitors in Chronic Pain: 2020-2030
- Wnt Pathway Inhibitors
- HGF Gene Therapy
- Major-Market Sales of HGF Gene Therapy in Chronic Pain: 2020-2030
- Key Findings
- Forecast
- Sales of Drugs to Treat Chronic Pain in the Major Pharmaceutical Markets by Indication: 2020
- Sales of Drugs to Treat Chronic Pain in the Major Pharmaceutical Markets: 2020, 2025, and 2030
- Etiology and Pathophysiology
- Disease Overview
- Etiology
- Conditions Causing Chronic Pain
- Chronic Pain Indications and Their Potential Pathophysiological Components
- Pathophysiology
- Nociceptive Pain
- Pathophysiological Components of Nociceptive, Inflammatory, and Neuropathic Pain
- Inflammatory Pain
- Neuropathic Pain
- Key Pathways and Drug Targets
- Ascending and Descending Pain Pathways
- Drug Targets in Chronic Pain
- Detailed Schematic of Nociceptive and Antinociceptive Pathways in the Dorsal Horn of the Spinal Cord
- Disease Overview
- Epidemiology
- Introduction
- Key Findings
- Key Updates
- Note About Our Epidemiology Populations
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Prevalent Cases of Rheumatoid Arthritic Pain
- Diagnosed Prevalent Cases of Rheumatoid Arthritic Pain in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
- Disease Definition
- Methods
- Sources Used for Diagnosed Prevalent Cases of Osteoarthritic Pain
- Diagnosed Prevalent Cases of Osteoarthritic Pain in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
- Disease Definition
- Methods
- Sources Used for Total Prevalent Cases of Cancer Pain
- Total Prevalent Cases of Cancer Pain in the Major Pharmaceutical Markets by Subtype: 2020-2030 (Thousands)
- Disease Definition
- Methods
- Sources Used for Total Prevalent Cases of Chronic Low Back Pain
- Total Prevalent Cases of Chronic Low Back Pain in Major Pharmaceutical Markets: 2020-2030 (Thousands)
- Disease Definition
- Methods
- Sources Used for Total Prevalent Cases of Fibromyalgia
- Total Prevalent Cases of Fibromyalgia in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
- Disease Definition
- Methods
- Sources Used for Total Prevalent Cases of Painful Diabetic Neuropathy
- Total Prevalent Cases of Painful Diabetic Neuropathy in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
- Disease Definition
- Methods
- Sources Used for Diagnosed Prevalent Cases of Postherpetic Neuralgia
- Diagnosed Prevalent Cases of Postherpetic Neuralgia in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
- Trigeminal Neuralgia
- Complex Regional Pain Syndrome
- Percentage Diagnosed
- Percentage Drug-Treated
- Percentage of Diagnosed and Drug-Treated Patients in Key Chronic Pain Populations: 2020-2030
- Introduction
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Chronic Pain
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Chronic Pain
- Current Treatments Used for Chronic Pain
- Market Events Impacting the Use of Key Current Therapies for Chronic Pain
- Advantages and Disadvantages of Select Antidepressants
- Expert Insight: Antidepressants
- Advantages and Disadvantages of Select Antiepileptic Drugs
- Expert Insight: Antiepileptic Drugs
- Advantages and Disadvantages of NSAIDs
- Expert Insight: NSAIDs
- Advantages and Disadvantages of COX-2-Selective NSAIDs
- Expert Insight: COX-2-Selective NSAIDs
- Transdermal Opioid Formulations
- Advantages and Disadvantages of Opioid Analgesics
- Expert Insight: Opioid Analgesics
- REMS for LA / ER Opioids
- Postmarketing Study Requirements for LA / ER Opioids
- Advantages and Disadvantages of Select Dual-Acting Opioid Analgesics
- Expert Insight: Dual-Acting Opioid Analgesics
- Advantages and Disadvantages of Opioid / NSAID or Acetaminophen Analgesics
- Expert Insight: Opioid / NSAID or Acetaminophen Combinations
- Advantages and Disadvantages of Select TRPV1 Agonists
- Expert Insight: TRPV1 Agonists
- Advantages and Disadvantages of Select Local Anesthetics
- Expert Insight: Local Anesthetics
- Advantages and Disadvantages of Cytokine Inhibitors
- Expert Insight: Cytokine Inhibitors
- Medical Practice
- Overview
- Country-Specific Chronic Pain Treatment Guidelines
- Factors Influencing Drug Selection in Chronic Pain
- Drug Selection in Chronic Pain in the United States
- Drug Selection in Chronic Pain in Europe
- Drug Selection in Chronic Pain in Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Chronic Pain
- Top Unmet Needs in Chronic Pain: Current and Future Attainment
- Expert Insight: Unmet Need in Chronic Pain
- Emerging Therapies
- Key Findings
- Pipeline Trends in Chronic Pain
- Key Emerging Therapies
- Therapies in Late-Phase Development for Chronic Pain
- Estimated Launch Dates of Key Emerging Therapies for the Treatment of Chronic Pain
- BIIB074 Profile
- Analysis of the Clinical Development Program for BIIB074
- Expert Insight: BIIB074
- Expectations for Launch and Sales Opportunity of BIIB074 in Chronic Pain
- NSAIDs and COX-2-Selective NSAIDs Profile
- Expert Insight: NSAIDs and COX-2-Selective NSAIDs
- Expectations for Launch and Sales Opportunity of NSAIDs and COX-2-Selective NSAIDs in Chronic Pain
- CAM2038 Profile
- Analysis of the Clinical Development Program for CAM2038
- Expert Insight: CAM2038
- Expectations for Launch and Sales Opportunity of CAM2038 in Chronic Pain
- Cebranopadol Profile
- Analysis of the Clinical Development Program for Cebranopadol
- Expert Insight: Cebranopadol
- Expectations for Launch and Sales Opportunity of Cebranopadol in Chronic Pain
- Oxycodone XR (Abuse-Deterrent, IntelliPharmaCeutics) Profile
- Analysis of the Clinical Development Program for Oxycodone XR (Abuse-Deterrent, IntelliPharmaCeutics)
- Expert Insight: Oxycodone XR (Abuse-Deterrent, Intellipharmaceutics)
- Expectations for Launch and Sales Opportunity of Oxycodone XR (Abuse-Deterrent, IntelliPharmaCeutics) in Chronic Pain
- Fasinumab Profile
- Analysis of the Clinical Development Program for Fasinumab
- Expectations for Launch and Sales Opportunity of Fasinumab in Chronic Pain
- Expert Insight: Anti-NGF Therapies
- Ampion (DMI-9523) Profile
- Analysis of the Clinical Development Program for Ampion (DMI-9523)
- Expert Insight: Ampion (DMI-9523)
- Expectations for Launch and Sales Opportunity of Ampion (DMI-9523) in Chronic Pain
- Engensis (VM202) Profile
- Analysis of the Clinical Development Program for Engensis (VM202)
- Expert Insight: Engensis (VM202)
- Expectations for Launch and Sales Opportunity of Engensis (VM202) in Chronic Pain
- Lorecivivint Profile
- Analysis of the Clinical Development Program for Lorecivivint
- Expert Insight: Lorecivivint
- Expectations for Launch and Sales Opportunity of Lorecivivint in Osteoarthritic Pain
- CNTX-4975 Profile
- Analysis of the Clinical Development Program for CNTX-4975
- Expert Insight: CNTX-4975
- Expectations for Launch and Sales Opportunity of CNTX-4975 in Osteoarthritic Pain
- Early-Phase Pipeline Analysis
- Select Therapies in Phase II Development for Chronic Pain
- Key Discontinuations and Failures in Chronic Pain
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Chronic Pain: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Chronic Pain: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Chronic Pain: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Chronic Pain
- Brands, Marketers, and Generic Availability of Current Therapies Used for Chronic Pain by Market
- Chronic Pain Bibliography
- Key Updates
Amanda Le, M.S., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. Prior to joining the company, she worked on research projects focusing on the effects of aging on the development of oral premalignancies, head and neck cancers, and handedness in surgery. She holds a master’s degree in medical sciences from Boston University School of Medicine and a bachelor’s degree in biochemistry from Boston College.